目的 評(píng)價(jià)阿托伐他汀和丹參酮聯(lián)用對(duì)慢性腎?。–KD）患者腎功能和糖脂代謝參數(shù)的影響。方法 前瞻性納入伴有白蛋白尿和血脂異常非透析性CKD患者90例，隨機(jī)分為觀察組（n=45）和對(duì)照組（n=45）。在CKD標(biāo)準(zhǔn)化治療的基礎(chǔ)上，對(duì)照組給予丹參酮ⅡA磺酸鈉注射液；觀察組加用阿托伐他汀鈣片10 mg/d。兩組療程均為6個(gè)月。比較兩組患者治療前后的糖脂代謝功能及肝腎功能。結(jié)果 治療半年后，兩組患者的總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）均下降，高密度脂蛋白膽固醇（HDL-C）增加，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組患者的TC、TG、LDL-C顯著低于對(duì)照組，HDL-C顯著高于對(duì)照組，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。所有患者對(duì)阿托伐他汀均耐受，兩組患者的天門冬氨酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）及肌酸激酶（CK）均無顯著性差異。觀察組和對(duì)照組患者的腎小球?yàn)V過率（eGFR）和高尿白蛋白肌酐比（UACR）無統(tǒng)計(jì)學(xué)差異。結(jié)論 他汀類藥物聯(lián)合丹參酮改善了CKD患者的血脂異常狀態(tài)，表現(xiàn)出一定的腎臟保護(hù)作用。

Objective The purpose of the present study was to examine possible therapeutic effects of statin combined with Tanshinone on renal function as well as parameters of lipid and glucose metabolism.Methods Ninety non-dialysis CKD Patients with albuminuria and dyslipidemia were prospectively enroled, and were randomly divided into observation group (n=45) and control group (n=45). Patients in the observation group were treated with Atorvastatin (10 mg/d) combined with Tanshinone, while patients in the control group were treated with Tanshinone only. We compared indexes of glucolipids metabolism and hepatorenal function between the two groups before therapy and six months after therapy.Results After six months treatment, the levels of TC, TG and LDL-C were decreased and HDL-C were increased in the two groups. The levels of TC, TG and LDL-C in the observation group were significantly lower than in the control group (P < 0.05). All patients were tolerant to atorvastatin. There was no significant difference in ALT, AST and creatine kinase between the two groups. There was no significant difference in eGFR and UACR between the two groups.Conclusions Statins combined with tanshinone improves dyslipidemia in CKD patients,which show a certain degree of renal protection.